Page 21 - Read Online
P. 21

Bax. J Transl Genet Genom 2020;4:1-16  I  http://dx.doi.org/10.20517/jtgg.2020.08                                                             Page 15

                   encephalomyopathy): hypergonadotropic hypogonadism. Hormones (Athens) 2012;11:377-9.
               70.   Debouverie M, Wagner M, Ducrocq X, Grignon Y, Mousson B, et al. MNGIE syndrome in 2 siblings. Rev Neurol (Paris) 1997;153:547-53.
               71.   Nishigaki Y, Martí R, Copeland WC, Hirano M. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine
                   phosphorylase deficiency. J Clin Invest 2003;111:1913-21.
               72.   Szigeti K, Wong LJC, Perng CL, Saifi GM, Eldin K, et al. MNGIE with lack of skeletal muscle involvement and a novel TP splice site
                   mutation. J Med Genet 2004;41:125-9.
               73.   Çelebi N, Şahin A, Canbay Ö, Uzümcügil F, Aypar U. Abdominal pain related to mitochondrial neurogastrointestinal encephalomyopathy
                   syndrome may benefit from splanchnic nerve blockade. Paediatr Anaesth 2006;16:1073-6.
               74.   Yavuz H, Özel A, Christensen M, Christensen E, Schwartz M, et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy
                   with dialysis. Arch Neurol 2007;64:435-8.
               75.   Granero Castro P, Fernández Arias S, Moreno Gijón M, Alvarez Martínez P, Granero Trancón J, et al. Emergency surgery in chronic
                   intestinal pseudo-obstruction due to mitochondrial neurogastrointestinal encephalomyopathy: case reports. Int Arch Med 2010;3:35.
               76.   Wang J, Chen W, Wang F, Wu D, Qian J, et al. Nutrition therapy for mitochondrial neurogastrointestinal encephalopathy with
                   homozygous mutation of the TYMP gene. Clin Nutr Res 2015;4:132-6.
               77.   Levene M, Bain M, Moran N, Nirmalananthan N, Poulton J, et al. Safety and efficacy of erythrocyte encapsulated thymidine
                   phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy. J Clin Med 2019;8.
               78.   Hafez H, Cordie A, Abdallah M, Hasaballah M, Elakel W, et al. Mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease: a
                   case report of a rare autosomal recessive inheritance with a poor prognosis. World J Pharm Sci 2014;2:1647-51.
               79.   Finkenstedt A, Schranz M, Bösch S, Karall D, Bürgi SS, et al. Mngie syndrome: liver cirrhosis should be ruled out prior to bone marrow
                   transplantation. JIMD Rep 2013;10:41-4.
               80.   Taivassalo T, De Stefano N, Argov Z, Matthews PM, Chen J, et al. Effects of aerobic training in patients with mitochondrial myopathies.
                   Neurology 1998;50:1055-60.
               81.   Yasumura S, Aso S, Fujisaka M, Watanabe Y. Cochlear implantation in a patient with mitochondrial encephalopathy, lactic acidosis and
                   stroke-like episodes syndrome. Acta Otolaryngol 2003;123:55-8.
               82.   Hirano M, Martí R, Casali C, Tadesse S, Uldrick T, et al. Allogeneic stem cell transplantation corrects biochemical derangements in
                   MNGIE. Neurology 2006;67:1458-60.
               83.   Filosto M, Scarpelli M, Tonin P, Lucchini G, Pavan F, et al. Course and management of allogeneic stem cell transplantation in patients
                   with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 2012;259:2699-706.
               84.   Bax BE, Bain MD, Scarpelli M, Filosto M, Tonin P, et al. Clinical and biochemical improvements in a patient with MNGIE following
                   enzyme replacement. Neurology 2013;81:1269-71.
               85.   De Giorgio R, Pironi L, Rinaldi R, Boschetti E, Caporali L, et al. Liver transplantation for mitochondrial neurogastrointestinal
                   encephalomyopathy. Ann Neurol 2016;80:448-55.
               86.   Röeben B, Marquetand J, Bender B, Billing H, Haack TB, et al. Hemodialysis in MNGIE transiently reduces serum and urine levels of
                   thymidine and deoxyuridine, but not CSF levels and neurological function. Orphanet J Rare Dis 2017;12:135.
               87.   Ariaudo C, Daidola G, Ferrero B, Guarena C, Burdese M, et al. Mitochondrial neurogastrointestinal encephalomyopathy treated with
                   peritoneal dialysis and bone marrow transplantation. J Nephrol 2014;28:125-7.
               88.   Sivadasan A, Muthusamy K, Patil AK, Mathew V, Alexander M. Pearls & Oy-sters: mitochondrial neurogastrointestinal
                   encephalomyopathy. Neurology 2016;86:e147-50.
               89.   Chandra VS, Lakshmi Sanggetha B, Padmavathi Devi SVV, Praveen N, Sameera NS, et al. Mitochondrial neurogastrointestinal
                   encephalomyopathy: a nonrenal indication for peritoneal dialysis. Indian J Nephrol 2018;28:310-3.
               90.   Salzer WL. Peritoneal dialysis-related peritonitis: Challenges and solutions. Int J Nephrol Renovasc Dis 2018;11:173-86.
               91.   Szeto CC, Li PKT. Peritoneal dialysis-associated peritonitis. Clin J Am Soc Nephrol 2019;14:1100-5.
               92.   Mihalache O, Bugă C, Doran H, Catrina E, Bobircă F, et al. Encapsulating peritoneal sclerosis - a rare and serious complication of
                   peritoneal dialysis: case series. J Med Life 2014;7:8-12.
               93.   Lara MC, Weiss B, Illa I, Madoz P, Massuet L, et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology
                   2006;67:1461-3.
               94.   Hussein E. Non-myeloablative bone marrow transplant and platelet infusion can transiently improve the clinical outcome of mitochondrial
                   neurogastrointestinal encephalopathy: a case report. Transfus Apher Sci 2013;49:208-11.
               95.   Blumberg N, Heal JM, Phillips GL. Platelet transfusions: trigger, dose, benefits, and risks. F1000 Med Rep 2010;2:5.
               96.   Godfrin Y, Horand F, Franco R, Dufour E, Kosenko E, et al. International seminar on the red blood cells as vehicles for drugs. Expert
                   Opin Biol Ther 2012;12:127-33.
               97.   Bax BE, Bain MD, Talbot PJ, Parker-Williams EJ, Chalmers RA. Survival of human carrier erythrocytes in vivo. Clin Sci 1999;96:171-8.
               98.   Bax BE, Levene M, Bain MD, Fairbanks LD, Filosto M, et al. Erythrocyte encapsulated thymidine phosphorylase for the treatment of
                   patients with mitochondrial neurogastrointestinal encephalomyopathy: study protocol for a multi-centre, multiple dose, open label trial. J
                   Clin Med 2019;8:1096.
               99.   Levene M, Pacitti D, Gasson C, Hall J, Sellos-Moura M, et al. Validation of an immunoassay for anti-thymidine phosphorylase antibodies
                   in patients with MNGIE treated with enzyme replacement therapy. Mol Ther Methods Clin Dev 2018;11:1-8.
               100.  Halter JP, Michael W, Schüpbach M, Mandel H, Casali C, et al. Allogeneic haematopoietic stem cell transplantation for mitochondrial
                   neurogastrointestinal encephalomyopathy. Brain 2015;138:2847-58.
               101.  Baker MK, Schutte CM, Ranchhod N, Brittain D, van Rensburg JE. Transient clinical improvement of a mitochondrial neurogastrointestinal
   16   17   18   19   20   21   22   23   24   25   26